Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 40.00 | |
10 mg | In stock | $ 68.00 | |
25 mg | In stock | $ 133.00 | |
50 mg | In stock | $ 197.00 | |
100 mg | In stock | $ 292.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 44.00 |
Description | Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment. |
In vitro | Rilematovir is highly active against a number of RSV strains from both A and B subtypes, especially the A2 strain. The EC50 of HeLa cells is 460 pM[1]. |
In vivo | Rilematovir efficiently suppresses established acute lower respiratory tract infection in the animals after oral treatment of neonatal lambs with Rilematovir, or with an equally active close analog[1]. |
Synonyms | JNJ-53718678, JNJ-678 |
Molecular Weight | 500.92 |
Formula | C21H20ClF3N4O3S |
CAS No. | 1383450-81-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 58.5mg/mL (116.8mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rilematovir 1383450-81-4 Angiogenesis JAK/STAT signaling Microbiology/Virology Tyrosine Kinase/Adaptors EGFR RSV JNJ 53718678 JNJ678 JNJ-53718678 JNJ53718678 JNJ 678 JNJ-678 inhibitor inhibit